Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
CBL0137 preferentially kills GSCs over NSTCs by targeting FACT. A, GSCs... | Download Scientific Diagram
CBL0137 HCl | ≥99%(HPLC) | Selleck | p53 activator
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
Acute exposure to CBL0137 decreases CD133 cell-surface expression and... | Download Scientific Diagram
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
em>TP53</em> loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137
FACT Complex-targeting Curaxin CBL0137 for Refractory Lymphomas Clinical Trial | Power
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Australian Researchers Find New Way to Target Deadly Childhood Cancer With CBL0137 | The Cure Starts Now
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
CBL0137 inhibits EPC in vitro. a A 13-nucleosome 601207 × 13 array for... | Download Scientific Diagram
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
CBL0137 | ≥99%(HPLC) | Selleck | NF-κB inhibitor
IJMS | Free Full-Text | Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers | HTML
Anticancer Drug Cbl0137 Highly Effective Against Infant Leukaemia | CCI
